High expression of TRIM11 correlates with poor prognosis in patients with hepatocellular carcinoma
High expression of TRIM11 correlates with poor prognosis in patients with hepatocellular carcinoma
复制标题
DOI：
10.1016/j.clinre.2016.09.010
复制
发表时间：
2017-03-01
影响因子：
2.7
通讯作者：
Xu, Geliang
中科院分区：
文献类型：
--
作者：
Chen, Yue;Li, Liang;Xu, Geliang
背景：TRIM蛋白家族成员TRIM 11在胶质瘤和肺癌中过表达。本研究的目的是探讨TRIM11在肝细胞癌（HCC）中的表达及其临床意义。主要发现：在本研究中，我们的数据显示TRIM11在HCC组织（n = 117）中的表达显著高于相匹配的非肿瘤肝（NTL）组织（P < 0.01）。与上述数据相一致，我们还发现TRIM 11蛋白表达与匹配的NTL相比显著增加（P < 0.01）。TRIM11蛋白表达与肝癌病理分级（P < 0.01）、术后转移（P = 0.031）、复发（P = 0.022）及血清甲胎蛋白（P < 0.01）有关。此外，患者的生存率与TRIM11蛋白表达呈负相关。此外，我们发现TRIM11蛋白是HCC患者无病生存期（P < 0.01）和总生存期（P < 0.01）的独立预后因素。TRIM11的过表达与HCC的进展和患者的低生存率密切相关，表明TRIM11是HCC患者的潜在治疗靶点。(C)2016 Elsevier Masson SAS。All rights reserved.
Background: Tripartite Motif Containing 11 (TRIM11), a member of TRIM proteins is overexpressed in gliomas and lung cancer. However, the role of TRIM11 in hepatocellular carcinoma (HCC) is unknown.Basic procedures: Herein, we aimed to investigate the expression and clinical significance role of TRIM11 in HCC.Main finding: In this study, our data showed significant higher TRIM11 in HCC tissues (n = 117) than in the matched non-tumor liver (NTL) tissues (P < 0.01). In consistent with above data, we also found TRIM11 protein expression was significantly increased compared with the matched NTL (P < 0.01) by immunohistochemistry analysis. Additionally, our results showed that TRIM11 protein expression in HCC tissues was significantly associated with pathological grade (P < 0.01), tumor postoperative metastasis (P = 0.031), recurrence (P = 0.022), and serum a-fetoprotein (AFP) (P < 0.01). Moreover, patients' survival was negatively correlated with TRIM11 protein expression. Furthermore, we found that TRIM11 protein was an independent prognostic factor for disease-free (P < 0.01) and overall survival (P < 0.01) in HCC patients.Principal conclusions: Our data showed that TRIM11 expression was significantly elevated in HCC tissues. The overexpression of TRIM11 is closely associated with HCC progression and poor survival of the patients, indicating TRIM11 is a potential therapeutic target for HCC patients. (C) 2016 Elsevier Masson SAS. All rights reserved.